Immunogenicity of Protein Therapeutics 2012

Immunogenicity continues to be a major concern for the biologics industry regarding its impact on safety and efficacy. This event examines factors that contribute to immunogenicity, development of predictive tools, and approaches to overcome this problem. It also presents expert advice on pre-clinical and clinical assessment strategies, risk assessment and regulatory considerations and guidance.